Peter DeYoung, CEO Piramal Global Pharma

Peter DeYoung is the CEO of Piramal Global Pharma and a member of the Piramal Pharma Operating Board. Piramal Global Pharma is comprised of Piramal Pharma Solutions and Piramal Critical Care business units. In his current role, Peter is responsible for steering strategy and driving profitable growth of these businesses.

Prior to this, he has spearheaded several leadership mandates at the Piramal Group, including CEO, Piramal Critical Care and President, Life Sciences.

Previously, Peter DeYoung worked in various investing and consulting roles in healthcare in the USA, Europe and India. He joined McKinsey & Company in New York after graduating from Princeton, where he worked on a number of projects for pharmaceutical and medical device companies. He was then seconded by McKinsey to the World Economic Forum in Geneva, Switzerland as part of the Global Health Initiative. Peter DeYoung returned to McKinsey in New York and later in Mumbai, where he focused on the pharmaceutical and healthcare practice. Later, he joined the Blackstone Group’s Private Equity Division in Mumbai where he was part of the deal team for several significant transactions, across a wide spectrum of industry sectors in India.

Peter DeYoung holds a Master’s Degree in Business Administration from Stanford University (Arjay Miller Scholar), California, USA and a Bachelor’s of Science Degree in Engineering from Princeton University, New Jersey, USA (summa cum laude).

Jeffrey Hampton, President & COO

Jeffrey Hampton is the President and Chief Operating Officer (COO) at Piramal Critical Care (PCC). At PCC, he leads the company’s Global Operations, Regulatory Affairs, Sales and Marketing, EHS, IT, Business and Product Development, and Program and Alliance Management functions. Jeffrey Hampton is responsible for driving PCC’s global business by leading strategy and developing growth plans, positioning the organization to capture market share in the industry, and building and sustaining relationships with Group Purchasing Organizations (GPOs), customers, channel partners, product developers and manufacturers.

Jeffrey Hampton’s career spans over three decades and his expertise lies across global sales and marketing, commercial operations, and distribution strategies for pharmaceutical organizations. Prior to joining PCC, Jeffrey Hampton was the President at Accord Healthcare and was responsible for accelerating the firm’s growth strategy. He has also held key positions at Apotex, Osmotica, Dabur and IVAX/Teva Pharmaceuticals.

Mr. Hampton holds a Bachelor of Science in Marketing from University of Florida and resides in North Carolina.

Rashida Najmi, Chief Quality Officer Piramal Pharma Limited

Rashida Najmi is Chief Quality Officer at Piramal Critical Care. She is responsible for establishing and implementing related quality standards, handling inspections, and maintaining regulatory track records of various regulatory agencies such as FDA, MHRA, and PMD.

Rashida maintains more than 26 years of experience in quality management of NDA, INDA, CRO, API- intermediates, API (drug substance), various dosage formulations (drug product), product development, clinical, pharmacovigilance, and biologic, with renowned companies like Shreya Life Sciences and ACG. During Rashida’s ongoing tenure at Piramal, she has successfully maintained the compliance benchmark higher than the regulatory requirement at all Pharma Solutions manufacturing sites across geographies. She is also instrumental in establishing ‘Quality’ as a differentiator for business growth and harmonizing “best in class” quality practices across Piramal.

Rashida is a Pharmacist and a postgraduate in Human Resources and is a Qualified Lead Auditor in ISO 9000 and ISO 14000 (from QMI, UK), certified in HACCP (from UN/ FAO), 5’S’ (from JMA), and OHSAS. In 2015, World Quality Congress awarded Rashida with the title of “50 Most Influential Quality Professionals.” She has been a jury member in several academic and quality awards and also an active member of industry forums like ISPE, IDMA, PDA, and OPPI.

Vikram Duggal, Sr. Vice President & Global HR Head Global Pharma

Vikram Duggal heads the Human Resources function at Piramal Critical Care (PCC). He has over two decades of experience in the field of designing and implementing organization transformation interventions, talent sourcing, talent management and employee relations in pharma manufacturing, consumer goods and financial services.

Previously, Vikram Duggal worked with organizations such as Sun Pharmaceuticals, Ranbaxy, PineBridge Investments (erstwhile AIG Investments), ICICI Prudential Life Insurance and Hindustan Unilever Limited.

Vikram Duggal holds a Master’s degree in HR from XLRI, Jamshedpur and a Bachelor’s degree in Science with a specialization in Statistics from Delhi University.

Michael Teague, Executive Vice President Global Operations

Michael Teague is the Executive Vice President of Global Operations at Piramal Critical Care. He is responsible for overseeing production planning & inventory control, order fulfillment, procurement, sourcing and vendor management, logistics, distribution and warehouse management, and vaporizer operations, including the management of the key vaporizer vendor relationships.

Mike began his career with Pfizer Inc. in the Groton Manufacturing Plant. Over the next 20 years, he was promoted through a series of positions overseeing pharmaceutical and chemical manufacturing and operations. After Pfizer, Mike consulted for many notable Fortune 500 firms such as Novartis, Pfizer, Fujisawa Pharmaceutical, Danisco, and Pepsi. During his time as a business development and pharmaceutical consultant, he traveled extensively where he was involved in due-diligence for acquisitions, joint-venture negotiations, competitive intelligence assessments, and technical transfers to Asia. In 2008, he headed a Bethlehem, Pennsylvania anesthetic manufacturing site, which was plagued with high costs, compliance and safety issues and an inability to meet demand prior to the Piramal acquisition in 2009, and turned it around. Today the site stands as a flagship site in the Piramal portfolio of operations. In 2012, Mike was promoted to Vice President of Supply Chain and charged with establishing and leading an integrated global supply chain for Piramal Critical Care. In 2021, Michael was promoted to Executive Vice President Global Operations.

Mike graduated from Worcester Polytechnic Institute with a Bachelor of Science in Chemical Engineering and currently resides in Lehigh Valley, Pennsylvania with his wife and two children.

Mahesh Sane, Sr. Vice President Finance

Mahesh Sane is the Sr. Vice President of Finance at Piramal Critical Care. Mahesh is responsible for the finance function of Piramal Critical Care’s global business spread across the United States, Europe, and India.

An experienced finance professional with more than 23 years of manufacturing industry experience, Mahesh began his career with Cadbury’s, a global food company, in Mumbai. With a career of multiple promotions and expanding functional expertise, Mahesh has worked across various industries such as food, steel, textile, chemicals, and pharmaceuticals. In 2007, Mahesh joined Piramal Group as General Manager (Divisional Controller) responsible for finance functions of the vitamin business. Within one year of vitamin business turnaround, Mahesh was promoted to manage the finance function of the Formulation Division of Piramal’s Contract Manufacturing business and in 2010 he took a new responsibility to lead the finance function of the Global Critical Care Business and relocated to the United States.

Throughout his career, Mahesh has been involved in providing strategic direction to business units and leading efforts to grow and turnaround businesses. His key contributions include strategic financial management and reporting, business unit re-engineering, budgeting and internal control, risk management, and banking relationships.

Mahesh earned his master’s degree in Commerce from Mumbai University, a professional qualification in Cost
Accounting from ICWA India, and acquired another professional qualification as Certified Chartered Accountant from ACCA in Glasgow, UK.

William Hargan, Sr. Vice President International Sales & Marketing

William Hargan is the Sr. Vice President International Sales & Marketing, RoW for Piramal Critical Care. He is responsible for leading the commercial teams for the European, Asian, Middle East, and Australian markets.

William started his career in the pharmaceutical industry in a sales role before progressing through product and international product management. He spent four years as Country Manager for Boots in Pakistan before leading the BASF Pharma international marketing team, where he was responsible for the worldwide introduction of Reductil. Following the acquisition by Abbott, William moved to lead the UK Hospital Division, which held a market-leading position in anesthesia. When it was spun out of Abbott, William joined Hospira and led the formation of the EMEA commercial team, including the recruitment of Country Managers for the European affiliates and the establishment and management of key distributor partnerships.

William has a BSc in Physiology from the University of Glasgow and lives in Surrey, England with his wife and two adult sons.

Hem Pandya, Sr. Vice President & Global Head Business Development & Strategic Alliances

Hem Pandya, Sr Vice President & Global Head Business Development & Strategic Alliances is an experienced pharmaceutical executive with a broad spectrum of commercial, operational, strategic, and corporate development experience with over 28 years in the pharmaceutical industry. Hem most recently served as the Head of the Generic Products Division for Mayne Pharmaceuticals (a publicly traded Australian Pharmaceutical Company) and was instrumental in the sale of the generic division to Dr. Reddy’s Laboratories in 2023.

Hem was the co-Founder & Chief Executive Officer of Vensun Pharmaceuticals, Inc. a generic specialty pharmaceutical company which was sold to Strides Pharmaceuticals, Inc. in 2019. Prior to Vensun, he was the President & Chief Executive Officer of Teligent (IGI) Inc. In past years, he has served in various senior executive roles for both private and publicly traded companies within the pharmaceutical industry.

Hem serves as a Director for non-profit organizations including the Boys and Girls Club of America of Mercer County, the Isles Foundation, and the Zimmerli Museum at Rutgers University.

Nick Dustman, Vice President North America Sales & Marketing

Nick is responsible for the sales and marketing function of Piramal Critical Care, Inc.

Nick has over twenty-four years of progressive leadership in the pharmaceutical industry.  He has extensive experience in the anesthetic inhaled agent and injectable market and has served as the Sr. Direct Sales for several brand and generic pharmaceutical companies.  Nick has a proven track record of success showcased through leadership roles at several companies such as Abbott, Bioniche/Mylan, American health Packaging, Ferring and Leucadia/Hikma.

Nick holds a Bachelor’s Degree in Business Administration from Pensacola Christian College in Florida.

Nick has two daughters and lives in Fernandina Beach, Florida with his wife.

Dr. Mark Aikman, Vice President Regulatory Affairs

Mark Aikman is a seasoned veteran of the pharmaceutical industry with over three decades of experience. After beginning his career as a practicing pharmacist in retail, hospital, and nursing home settings, in the late 1980’s he began his career in the pharmaceutical industry while he went back to school part-time to obtain his Doctor of Pharmacy degree.

Mark Aikman has worked in a variety of roles over the years. While most of the time was spent in regulatory and quality roles, he also has spent a brief period in sales and marketing as the Managing Director of Kremers Urban where he was instrumental in the development of generic omeprazole, a blockbuster product for the US market.

Mark Aikman’s experience covers a large extent of regulatory pathways from NDAs, ANDAs, 505(b)(2)s, and 510Ks, as well as ex-US applications. He has been instrumental in the US development, approval, and commercialization of successful 505(b)(2) products and difficult generics. He also has a firm understanding of both clinical development and medical affairs in the pre-launch and post-commercial arenas.